Brief: Guangzhou Innogen Pharmaceutical Posts FY Revenue Rmb131.5 Million
23/03/2026 15:18
March 23 (Reuters) - Guangzhou Innogen Pharmaceutical 2591.HK: FY REVENUE RMB131.5 MILLION FY LOSS ATTRIBUTABLE RMB341.4 MILLION PLANS TO ENTER THE LATIN AMERICA MARKET Further company coverage: 2591.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Guangzhou Innogen Pharmaceutical
See all newsBrief: Guangzhou Innogen Pharmaceutical Appoints Jin Bai As Vice President
Brief: Guangzhou Innogen Pharmaceutical Says Xu Wenjie Resigns As Executive Director
Brief: Guangzhou Innogen Pharmaceutical Group Co's Founder, Senior Management Undertakes Six-Month Lock-Up
Brief: Guangzhou Innogen Pharmaceutical Announces Intention To Conduct On-Market H Share Repurchase
Brief: GUANGZHOU INNOGEN PHARMACEUTICAL Posts HY LOSS Of RMB115.5 MLN